190 related articles for article (PubMed ID: 26262134)
1. Conceptual Knowledge Discovery in Databases for Drug Combinations Predictions in Malignant Melanoma.
Regan K; Raje S; Saravanamuthu C; Payne PR
Stud Health Technol Inform; 2015; 216():663-7. PubMed ID: 26262134
[TBL] [Abstract][Full Text] [Related]
2. Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.
Regan-Fendt KE; Xu J; DiVincenzo M; Duggan MC; Shakya R; Na R; Carson WE; Payne PRO; Li F
NPJ Syst Biol Appl; 2019; 5():6. PubMed ID: 30820351
[TBL] [Abstract][Full Text] [Related]
3. [Current aspects in the prognosis of advanced melanoma].
Sirokay-Kohlmeyer J
Hautarzt; 2018 Mar; 69(3):249-259. PubMed ID: 29396638
[TBL] [Abstract][Full Text] [Related]
4. An RDF/OWL knowledge base for query answering and decision support in clinical pharmacogenetics.
Samwald M; Freimuth R; Luciano JS; Lin S; Powers RL; Marshall MS; Adlassnig KP; Dumontier M; Boyce RD
Stud Health Technol Inform; 2013; 192():539-42. PubMed ID: 23920613
[TBL] [Abstract][Full Text] [Related]
5. Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process-A systematic review.
Guerrisi A; Loi E; Ungania S; Russillo M; Bruzzaniti V; Elia F; Desiderio F; Marconi R; Solivetti FM; Strigari L
Cancer Med; 2020 Mar; 9(5):1603-1612. PubMed ID: 31951322
[TBL] [Abstract][Full Text] [Related]
6. Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials.
Grob JJ; Long GV; Schadendorf D; Flaherty K
Lancet Oncol; 2015 Oct; 16(13):e522-6. PubMed ID: 26433825
[TBL] [Abstract][Full Text] [Related]
7. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
8. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
[TBL] [Abstract][Full Text] [Related]
9. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy of malignant melanoma].
Ishihara K; Yamazaki N; Asano K
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1287-92. PubMed ID: 7688498
[TBL] [Abstract][Full Text] [Related]
11. The TOKEn project: knowledge synthesis for in silico science.
Payne PR; Borlawsky TB; Lele O; James S; Greaves AW
J Am Med Inform Assoc; 2011 Dec; 18 Suppl 1(Suppl 1):i125-31. PubMed ID: 21984589
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in the management of advanced cutaneous malignant melanoma.
Luke JJ; Schwartz GK
Clin Dermatol; 2013; 31(3):290-7. PubMed ID: 23608448
[TBL] [Abstract][Full Text] [Related]
13. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy in the treatment of malignant melanoma.
Lens MB; Eisen TG
Expert Opin Pharmacother; 2003 Dec; 4(12):2205-11. PubMed ID: 14640919
[TBL] [Abstract][Full Text] [Related]
15. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
Zia Y; Chen L; Daud A
Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
[TBL] [Abstract][Full Text] [Related]
16. Marker utility for combination therapy.
Simeone E; Grimaldi AM; Ascierto PA
Methods Mol Biol; 2014; 1102():97-115. PubMed ID: 24258976
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Treatments for Advanced Resectable Melanoma.
Liu JY; Lowe M
J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
[TBL] [Abstract][Full Text] [Related]
18. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA
Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of metastatic melanoma.
Houghton AN; Meyers ML; Chapman PB
Surg Clin North Am; 1996 Dec; 76(6):1343-54. PubMed ID: 8977555
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy for disseminated malignant melanoma.
Abbott KL; Harman GS
Anticancer Drugs; 1995 Aug; 6(4):489-97. PubMed ID: 7579552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
